<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927170</url>
  </required_header>
  <id_info>
    <org_study_id>GLH1SM-102</org_study_id>
    <nct_id>NCT03927170</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers(Fed)</brief_title>
  <official_title>A Randomized, Open-label, Fed, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics of GLH1SM Extended Release Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crossover study to compare the pharmacokinetic characteristics of GLH1SM sustained release
      tablet and Janumet XR tablet in fed condition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 X 2 crossover study to compare the pharmacokinetic characteristics and safety of GLH1SM
      sustained release 100/1000mg tablet and Janumet XR 100/1000mg tablet
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">September 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt in ng·h/mL</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax in ng/mL</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf in ng·h/mL</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in hour</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 in hour</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F in Liter/min/kg</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F in Liter/kg</measure>
    <time_frame>24 hours</time_frame>
    <description>Metformin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 day before IP administration, 1 day, 2 day, 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>To 28 days after last IP administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs in blood pressure</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day and 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>Blood pressure(SBP, DBP)</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs in pulse</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day and 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>Pulse rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs in temperature</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day and 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>eardrum</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examinations in weight</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day before IP administration, 1 day, 2 day, 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>Weight in kilograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examinations in height</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day before IP administration, 1 day, 2 day, 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>Height in meters</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical laboratories in blood sample</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), 1 day before IP administration, and 3 day of each period, and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>Normal blood chemistry, Type B hepatitis, Type C hepatitis, HIV, and Syphilis</description>
  </other_outcome>
  <other_outcome>
    <measure>12-lead ECG in clinical significance</measure>
    <time_frame>Screening(between 2 day and 28 day before IP administration), and one day between 3 day and 7 day after last blood sampling</time_frame>
    <description>QRS complex</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLH1SM tablet 100/1000 mg in FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Janumet XR tablet 100/1000 mg in FDC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Janumet XR tablet 100/1000 mg</intervention_name>
    <description>To administrate the Janumet XR tablet</description>
    <arm_group_label>Janumet XR tablet 100/1000 mg in FDC</arm_group_label>
    <other_name>Sitagliptin and Metformin in Fixed Dose Combination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GLH1SM tablet 100/1000 mg</intervention_name>
    <description>To administrate the GLH1SM tablet</description>
    <arm_group_label>GLH1SM tablet 100/1000 mg in FDC</arm_group_label>
    <other_name>Sitagliptin and Metformin in Fixed Dose Combination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects who, at the time of screening, are the age of older than 19
             years

          -  Subjects who have BMI more than 17.5kg/m2 and less than 30.5kg/m2 and body weight more
             than 55kg

          -  There is no congenital disease or within 3 years of chronic diseases

          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead electrocardiogram (ECG) or clinical laboratory tests

          -  Subjects who signed and dated the informed consent form(approved by IRB) after
             understanding fully to hear a detailed explanation in the clinical trial

          -  Subjects who are willing and able to comply with all scheduled visits, treatment plan,
             laboratory tests, and other study procedures

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing)

          -  A subject with any history of gastrointestinal disease (e.g., Crohn's disease, acute
             or chronic pancreatitis, and others) and surgery (except for simple appendectomy or
             repair of a hernia), which can influence the absorption of investigational products

          -  A subject who has the following clinical laboratory test results Liver Function Test
             (AST, ALT) &gt; two times the upper limit of the normal range

          -  History of regular alcohol consumption exceeding 210g/week(12g = 125 mL of wine, 10g =
             250 mL of beer, 10g = 50 mL of hard liquor) within 6 months of Screening

          -  A subject who has participated in any other clinical trials and had medication within
             3 months prior to the first administration of investigational product. (The end date
             of another clinical trial is based on the last day of the administration)

          -  A subject with a history of drug abuse or a positive urine drug screening for drug
             abuse within 1 year

          -  A subject who has taken the drugs that induce and suppress drug- metabolizing enzymes
             within 30 days prior to investigational product administration

          -  A smoker who consumes more than 20 cigarettes/day within 6 months

          -  A subject who has taken any ethical-the-counter drug or has taken any over-
             the-counter drug within 10 days before the investigational product administration

          -  A subject who has donated whole blood within 2 months or blood components within 1
             month prior to the investigational product administration

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation

          -  Acute effects that may affect renal function in patients with moderate and severe
             renal failure (eGFR&lt;45 mL/min/1.73m2) such as sepsis, dehydration, severe infection,
             cardiovascular collapse, acute myocardial infarction

          -  Acute and unstable heart failure

          -  Patients receiving intravenous administration of radiation iodine contrast media (eg,
             intravenous urography, venous cholangiography, angiography, computed tomography using
             contrast media, etc.)

          -  Patients who are known to be hypersensitive to anaphylaxis or angioedema for the drug
             or its components

          -  Patients with acute or chronic metabolic acidosis, including type 1 diabetes, diabetic
             ketoacidosis with or without coma, and patients with a history of ketoacidosis

          -  Patients with severe infectious disease or severe traumatic systemic disorder

          -  Abnormal diet that may affect absorption, distribution, metabolism and excretion of
             drugs

          -  Pregnant women, women who may be pregnant, breastfeeding

          -  A subject who is not eligible for the study due to reasons on the investigators'
             judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungho Jang, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

